Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The Efficacy and Safety of Dolutegravir-based Dual Therapies in HIV-infected Patients With Intolerance or Toxicity to Nucleoside Analogues

Next Previous
Trial Profile

The Efficacy and Safety of Dolutegravir-based Dual Therapies in HIV-infected Patients With Intolerance or Toxicity to Nucleoside Analogues

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 24 Jan 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cobicistat (Primary) ; Darunavir (Primary) ; Dolutegravir (Primary) ; Rilpivirine (Primary)
  • Indications HIV infections
  • Focus Therapeutic Use
  • Acronyms DOLBI

Most Recent Events

  • 09 Nov 2019 Results assessing the effect of switching to dolutegravir-based dual therapy on body composition and factors associated with these changes published in the AIDS
  • 31 Oct 2018 Results (n=102) assessing the safety and efficacy of the dual regimen of dolutegravir plus rilpivirine in patients with toxicity or drug-drug interactions, presented at the 14th International Congress on Drug Therapy and HIV Infection.
  • 29 Jun 2018 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top